# US 2014/0193382 A1 · Endogenous Expression of HLA-G and/or HLA-E by Mesenchymal Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193382 A1
- Document ID: US20140193382A1
- Status: Published application
- Kind: A1
- Application number: 14/102,368
- Filed: 2013-12-10
- Published: 2014-07-10
- Earliest claimed: 2007-03-30
- Assignees: Escape Therapeutics, Inc.
- Applicants: Escape Therapeutics, Inc.
- Inventors: Basil M. HANTASH
- Web page: https://patentgrep.com/patent/US20140193382A1

## CPC

- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- C12N 15/85: for animal cells
- G01N 33/56977: {HLA or MHC typing}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and compositions are provided for the identification and isolation of mammalian HLA-G+ MSC, HLA-E+ MSC, or HLA-G+/HLA-E+ MSC. The methods of the invention provide a means to obtain enriched HLA-G+ MSC, HLA-E+ MSC, or HLA-G+/HLA-E+ MSC populations.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method of cell transplantation into a human recipient, the method comprising:
(a) providing an isolated composition of human cells comprising an enriched population of human adult adipose tissue derived mesenchymal stem cells or bone marrow-derived mesenchymal stem cells, wherein at least 90% of said mesenchymal stem cells express cell surface HLA-G, HLA-E, or both HLA-G and HLA-E, and upon initial isolation from adipose tissue or bone marrow tissue, maintain cell surface expression of HLA-G, HLA-E, or both HLA-G and HLA-E, after at least two passages in non-differentiating in vitro culture conditions; and
(b) injecting the isolated composition of step (a) into a human recipient, wherein the cells of the isolated composition of step (a) are allogeneic or autologous with respect to the human recipient, and wherein a perfect match of histocompatibility antigens is not required between the isolated composition of human cells of step (a) and the human recipient.

### Claim 17 (depends on 16)

The method of claim 16, wherein the human recipient suffers from a degenerative disease.

### Claim 18 (depends on 16)

The method of claim 16, wherein the human adult adipose tissue derived mesenchymal stem cells or bone marrow-derived mesenchymal stem cells of step (a) further comprises an exogenous nucleic acid.

### Claim 19 (depends on 18)

The method of claim 18, wherein the exogenous nucleic acid comprises a sequence encoding HLA-G or HLA-E.

### Claim 20 (depends on 18)

The method of claim 18, wherein the exogenous nucleic acid comprises a sequence encoding a growth factor.

### Claim 21 (depends on 18)

The method of claim 18, wherein the exogenous nucleic acid comprises a sequence encoding dystrophin.

### Claim 22 (depends on 16)

The method of claim 16, further comprising the step of co-injecting with the isolated composition of human cells of step (a), cells selected from the group consisting of hematopoietic stem cells, progenitors of hematopoietic stem cells, cardiomyocytes, progenitors of cardiomyocytes, neurons, progenitors of neurons, pancreatic islet cells, muscle satellite cells, endothelial cells, and progenitors of endothelial cells.